Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children[J]. Br J Haematol, 2008, 142(3): 329-347.
[2]
Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymogomas: a clinicopathologic analysis of cases included in the German BFM(Berlin-Frankfurt-Munster) Multicenter Trial[J]. Blood, 2006, 107(10): 4047-4052.
[3]
Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults[J]. Semin Oncol, 1980, 7(3): 332-339.
[4]
Pillon M, Di Tullio MT, Garaventa A, et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)[J]. Cancer, 2004, 101(2): 385-394.
[5]
Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients[J]. Blood, 2007, 109(7): 2773-2780.
[6]
Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB96 international study[J]. Br J Haematol, 2008, 141(6): 840-847.
[7]
Cairo MA, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents[J]. Blood, 2007, 109(7): 2736-2743.
[8]
NCI. CTCAE[EB/OL].[May 17, 2010].
[9]
Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age(≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study[J]. J Clin Oncol, 2012, 30(4): 387-393.
[10]
Lones MA, Raphael M, Perkins SL, et al. Mature B-cell lymphoma in children and adoescents: International group pathologist consensus correlates with histology technical quality[J]. J Pediatr Hematol Oncol, 2006, 28(9): 568-574.
Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell lymphoblastic leukemia: a report from the Children's Oncology Group[J]. Pediatr Blood Cancer, 2009, 52(2): 177-181.
[14]
Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents[J]. Biol Blood Marrow Transplant, 2010, 16(2): 223-230.
